PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
30.46%
Revenue growth of 30.46% while CRON.TO is flat. Bruce Berkowitz would check if a small edge can widen further.
41.93%
Gross profit growth under 50% of CRON.TO's 1172.95%. Michael Burry would be concerned about a severe competitive disadvantage.
82.60%
EBIT growth 1.25-1.5x CRON.TO's 70.44%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
82.60%
Operating income growth similar to CRON.TO's 85.71%. Walter Schloss would assume both share comparable operational structures.
100.85%
Net income growth 1.25-1.5x CRON.TO's 87.84%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
101.37%
EPS growth 1.25-1.5x CRON.TO's 91.82%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
100.00%
Similar diluted EPS growth to CRON.TO's 91.82%. Walter Schloss might see standard sector or cyclical influences on both firms.
20.86%
Share reduction more than 1.5x CRON.TO's 48.41%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
61.58%
Diluted share count expanding well above CRON.TO's 48.41%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-1.79%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
16.41%
Positive FCF growth while CRON.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.23%
OCF/share CAGR of 81.23% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
81.23%
OCF/share CAGR of 81.23% while CRON.TO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
35.95%
3Y OCF/share CAGR of 35.95% while CRON.TO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
100.20%
10Y net income/share CAGR of 100.20% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
100.20%
Net income/share CAGR of 100.20% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
101.39%
3Y net income/share CAGR of 101.39% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
172.44%
Equity/share CAGR of 172.44% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
172.44%
Equity/share CAGR of 172.44% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
350.35%
Equity/share CAGR of 350.35% while CRON.TO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.68%
AR growth of 26.68% while CRON.TO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-10.75%
Inventory is declining while CRON.TO stands at 5079.86%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
100.93%
Asset growth at 50-75% of CRON.TO's 148.26%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
76.87%
BV/share growth above 1.5x CRON.TO's 32.58%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
42.65%
R&D growth of 42.65% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
3.32%
SG&A declining or stable vs. CRON.TO's 103.38%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.